Skip to main content
Infectious Diseases
Resource Center
Menu
Menu
Main navigation
Home
Education
Featured Topics
Acute Hepatic Porphyria
Alzheimer Disease
COVID-19
Depression Care 360
Diabetes Technology
Digital Health Solutions in Diabetes
HER2-Positive Early Breast Cancer
HIV Management
Neuromyelitis Optica Spectrum Disorder
Primary Hyperoxaluria
Ulcerative Colitis
Resources
Atlas of Lumps and Bumps
Case Presentations
Commentary
Disease State and Specialty Directory
FDA Alerts
Pearls
Podcasts
Polls
Q&A
Quizzes
Research Summaries
Slideshows
Videos
Multidisciplinary Roundtables
Featured Conferences
ACR Convergence
AIBD
American Heart Association Scientific Sessions
American Association of Neurological Surgeons Annual Meeting
American Society of Hematology Annual Meeting & Exposition
Consultant360's Practical Updates in Primary Care
Conference on Retroviruses and Opportunistic Infections
Infectious Diseases Society of America’s IDWeek
Society of Gynecologic Oncology Annual Meeting
International AIDS Conference
Society of Hematologic Oncology's Annual Meeting
Clinical Updates
Allergic Asthma
Alzheimer Disease
Cardiovascular Disease
Endometrial Cancer
Endometriosis
Eosinophilic Disorders
Exocrine Pancreatic Insufficiency
Generalized Pustular Psoriasis
Major Depressive Disorder
Nasal Polyps
Ovarian Cancer
Rheumatoid Arthritis
Schizophrenia
Ulcerative Colitis
Publication
About Consultant
Advertising With Consultant360
Author Guidelines
Call for Papers
Case Report Templates
Consultant Current Issue
Consultant Archive
Consultant Early View
FAQ
Get Permissions
Job Board
Get Permissions
Search
Contact
Login
Menu
Menu
Main navigation
Home
Education
Featured Topics
Acute Hepatic Porphyria
Alzheimer Disease
COVID-19
Depression Care 360
Diabetes Technology
Digital Health Solutions in Diabetes
HER2-Positive Early Breast Cancer
HIV Management
Neuromyelitis Optica Spectrum Disorder
Primary Hyperoxaluria
Ulcerative Colitis
Resources
Atlas of Lumps and Bumps
Case Presentations
Commentary
Disease State and Specialty Directory
FDA Alerts
Pearls
Podcasts
Polls
Q&A
Quizzes
Research Summaries
Slideshows
Videos
Multidisciplinary Roundtables
Featured Conferences
ACR Convergence
AIBD
American Heart Association Scientific Sessions
American Association of Neurological Surgeons Annual Meeting
American Society of Hematology Annual Meeting & Exposition
Consultant360's Practical Updates in Primary Care
Conference on Retroviruses and Opportunistic Infections
Infectious Diseases Society of America’s IDWeek
Society of Gynecologic Oncology Annual Meeting
International AIDS Conference
Society of Hematologic Oncology's Annual Meeting
Clinical Updates
Allergic Asthma
Alzheimer Disease
Cardiovascular Disease
Endometrial Cancer
Endometriosis
Eosinophilic Disorders
Exocrine Pancreatic Insufficiency
Generalized Pustular Psoriasis
Major Depressive Disorder
Nasal Polyps
Ovarian Cancer
Rheumatoid Arthritis
Schizophrenia
Ulcerative Colitis
Publication
About Consultant
Advertising With Consultant360
Author Guidelines
Call for Papers
Case Report Templates
Consultant Current Issue
Consultant Archive
Consultant Early View
FAQ
Get Permissions
Job Board
Get Permissions
Advertisement
Chronic Pain
Pop Quiz: Opioid Analgesics in HIV
Copied to clipboard
<section><h2></h2></section><section><h2><p><strong></strong>TRUE OR FALSE: According to the <a href="https://academic.oup.com/cid/article/65/10/e1/4157299" target="_blank">2017 HIV Medical Association (HIVMA) of Infectious Diseases Society of America’s (IDSA) Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV</a>, opioid analgesics should be given as a first-line therapy for long-term management of chronic neuropathic pain in patients with HIV. </p></h2></section><section><h2><p>Better luck next time</p></h2><p><p><span style="color: rgb(42, 42, 42);">The guidelines also include the following weak recommendation: “Clinicians may consider a time-limited trial of opioid analgesics for patients who do not respond to first-line therapies and who report moderate to severe pain. As a second- or third-line treatment for chronic neuropathic pain, a typical adult regimen should start with the smallest effective dose and combine short- and long-acting opioids.”</span></p><p><br></p><p><span style="color: rgb(42, 42, 42);">For more HIV content, visit the </span><a href="https://www.consultant360.com/specialty/infectious-diseases/hiv-management" target="_blank">Resource Center</a><span style="color: rgb(42, 42, 42);">.</span></p></p></section><section><h3><p>Nice job!</p></h3><p><p><span style="color: rgb(42, 42, 42);">The guidelines also include the following weak recommendation: “Clinicians may consider a time-limited trial of opioid analgesics for patients who do not respond to first-line therapies and who report moderate to severe pain. As a second- or third-line treatment for chronic neuropathic pain, a typical adult regimen should start with the smallest effective dose and combine short- and long-acting opioids.”</span></p><p><br></p><p><span style="color: rgb(42, 42, 42);">For more HIV content, visit the </span><a href="https://www.consultant360.com/specialty/infectious-diseases/hiv-management" target="_blank">Resource Center</a><span style="color: rgb(42, 42, 42);">.</span></p></p></section>
advertisement
Advertisement
Advertisement
